Summary of Anticholinergic Pharmacotherapy Available for Overactive Bladder Dysfunction

被引:0
|
作者
Mangera, Altaf [1 ]
Chapple, Christopher R. [2 ]
机构
[1] Royal Hallamshire Hosp, Sheffield Teaching Hosp NHS Trust, Dept Urol Res, Sheffield, S Yorkshire, England
[2] Sheffield Hallam Univ, Royal Hallamshire Hosp, Room H26,H-Floor,Glossop Rd, Sheffield S10 2JF, S Yorkshire, England
关键词
Overactive bladder syndrome; Anticholinergic therapy; Oxybutynin; Solifenacin; Tolterodine; Fesoterodine; Darifenacin; Propiverine; Trospium;
D O I
10.1007/s11884-011-0114-7
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Bladder over activity affects many individuals worldwide. Anticholinergic therapy has become standard first-line pharmacotherapy for overactive bladder dysfunction after failure of conservative measures. Several different anticholinergic agents are currently utilized in clinical practice. In this article, we review the mechanism of action of these drugs. This review aims to summarize the contemporary evidence base behind the use of these agents in terms of efficacy, safety, and patient satisfaction. Anticholinergic agents lead to improvements in symptoms of urgency, frequency, and urgency incontinence; however, there are associated side effects related to dry mouth, pruritus, constipation, and the central nervous system.
引用
收藏
页码:51 / 58
页数:8
相关论文
共 50 条
  • [1] Summary of Anticholinergic Pharmacotherapy Available for Overactive Bladder Dysfunction
    Altaf Mangera
    Christopher R. Chapple
    Current Bladder Dysfunction Reports, 2012, 7 (1) : 51 - 58
  • [2] Summary of Anticholinergic Pharmacotherapy Available for Overactive Bladder
    Olufenwa Famakinwa
    Charles Chang
    Doreen E. Chung
    Current Bladder Dysfunction Reports, 2012, 7 (1) : 40 - 50
  • [3] Summary of Anticholinergic Pharmacotherapy Available for Overactive Bladder
    Famakinwa, Olufenwa
    Chang, Charles
    Chung, Doreen E.
    CURRENT BLADDER DYSFUNCTION REPORTS, 2012, 7 (01) : 40 - 50
  • [4] Pharmacotherapy in overactive bladder
    Hopkinson, V. C. G.
    Pearce, I.
    JOURNAL OF CLINICAL UROLOGY, 2018, 11 (01) : 38 - 47
  • [5] The pharmacotherapy of overactive bladder
    Athanasopoulos, Anastasios
    EXPERT OPINION ON PHARMACOTHERAPY, 2011, 12 (07) : 1003 - 1005
  • [6] Anticholinergic drugs for overactive bladder
    Kuteesa, William
    Moore, Kate H.
    AUSTRALIAN PRESCRIBER, 2006, 29 (01) : 22 - 24
  • [7] Pharmacotherapy of overactive bladder: epidemiology and pathophysiology of overactive bladder
    Latini, Jerilyn M.
    Giannantoni, Antonella
    EXPERT OPINION ON PHARMACOTHERAPY, 2011, 12 (07) : 1017 - 1027
  • [8] Anticholinergic drugs for overactive bladder
    Kripke, C
    AMERICAN FAMILY PHYSICIAN, 2006, 73 (01) : 66 - 66
  • [9] Anticholinergic drugs in overactive bladder
    Muhlstein, J.
    Deval, B.
    GYNECOLOGIE OBSTETRIQUE & FERTILITE, 2008, 36 (01): : 90 - 96
  • [10] Developments in the pharmacotherapy of the overactive bladder
    Sellers, Donna J.
    McKay, Neil
    CURRENT OPINION IN UROLOGY, 2007, 17 (04) : 223 - 230